Introduction
SSc is characterized by tissue fibrosis whose pathogenesis is partially elucidated [1] . A biomarker of overall fibrosis and fibrogenesis has been an unmet need for a long time and would aid the fulfillment of the need for a molecular classification of patients with SSc, and their stratification for the level of profibrotic activity [24] . For these purposes, we have recently proposed the enhanced liver fibrosis (ELF) test, a serum test originally developed and validated on chronic liver fibrosis diseases [5] and, more recently, shown to be a marker of overall fibrosis in SSc mainly reflecting skin and lung involvement [6] . It is an algorithm that includes the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and HA, all markers known to be involved in the process of fibrogenesis and/or extracellular matrix (ECM) remodeling [6] . In a single centre cohort of 210 SSc patients, none of the three biomarkers was found to be significantly associated with any vascular manifestation of the disease [6] . This study aimed to determine the value of the ELF score and its single analytes in an independent multicentre cohort of SSc patients.
Methods
Patients and sera samples Two hundred and fifty-four SSc patients from six European rheumatology centres were included in this study. Ethical approval was obtained by the Leeds Teaching Hospitals Trust Committee (LTHT REC 10/H1306/88); clinical data and serum samples collection was approved by each local institutional ethics committee (Comitato Etico di Area Vasta Centro, Toscana, Azienda Ospedaliera Universitaria Careggi, Firenze; Comite de protection des personnes Ile de France 3; Comitato Etico Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Roma; Ethikkommission Kanton Zü rich; NRES Committee London-Hampstead). All patients fulfilled the 2013 ACR/EULAR classification criteria for SSc [7] . Clinical data were collected at time of sampling and included a wide set of variables, as previously described [6] . Serum samples were collected and stored in each participant centre according to EUSTAR biobanking recommendations [8] . The 254 sera were analysed employing a high-throughput in vitro diagnostic (Siemens AlphaCentaur). Cut-off values of ELF test were applied in line with recommendations from Siemens Healthcare Diagnostics (<7.7 = no-mild fibrosis; 57.7 to <9.8 = moderate fibrosis; 59.8 to <12 = severe fibrosis/cirrhosis; 512 = cirrhosis).
Statistics
Statistical analysis was performed as previously described using SPSS software for Mac v.24.0 [6] . Items found to show a significant correlation (P < 0.05) in univariate analysis were then tested in stepwise regression analysis to evaluate which baseline variables were independently associated with the ELF score and its single analytes.
Results
Two hundred and fifty-four SSc patients were originally included in this study. Seven patients had viral hepatitis positivity in absence of cirrhosis/liver fibrosis; one more patient, hepatitis C virus positive, had a history of liver transplantation. Fourteen patients were anti-mitochondrial antibody positive, seven of them had associated primary biliary cholangitis (PBC). Eleven patients had SSc in overlap with another rheumatic disease (three with Sjö gren's syndrome, four with dermatomyositis/polymyositis, one with systemic lupus erythematosus, one with rheumatoid arthritis, one with MPO positive vasculitis, one with mixed connective tissue disease). To investigate whether liver disease could influence the ELF score, we first analysed the difference between the infectious viral hepatitis group (n = 8), the PBC group (n = 7) and the rest of the cohort. Mean ELF score and age were not significantly different (P > 0.05) between the two disease groups and the rest of the cohort with unknown liver condition. However, based on the normal modified Rodnan skin score (mRSS) (= 0), absence of SSc-related fibrosis signs, also including chest high resolution computed tomography (HRCT) scan, ELF score was unexpectedly high (10.89 and 10.85 respectively) in two lcSSc patients who had associated PBC, suggesting that cholangitis was influencing the fibrotic score. We therefore excluded from the subsequent analyses the seven patients with diagnosis of PBC.
Supplementary Table S1 , available at Rheumatology online, shows the clinical characteristics of the multicentre cohort of 247 SSc patients. They are quite similar to those of the original cohort in which the ELF test has been originally tested in the context of SSc [6] . Two-hundred and two (81.8%) were women, 80 (32.4%) were classified as having dcSSc. One-hundred and four patients (42.1%) were positive for anticentromere antibody, and 57 (23.1%) were antitopoisomerase-1 positive. As in the first study, this multicentre cohort of 247 SSc patients was heterogeneous with regard to organ involvement, disease activity [9] and severity [10] . Total Medsger's severity score, sum of the nine severity scores, ranged between 1 and 19. The EScSG-AI ranged between 0 and 7.5. At the time of sampling, 110 patients (44.5%) were taking immunosuppressive/anti-rheumatic drugs including corticosteroids and/or cyclophosphamide, mycophenolate, azathioprine, methotrexate and hydroxychloroquine.
The ELF score ranged from 6.212.1 with a mean of 8.9 (±1.1). Two hundred and nineteen (88.7%) patients had an abnormal ELF test (57.7). Distribution of age, mRSS, EScSG-AI and Medsger's total severity score among the four ELF reference ranges is shown in Fig. 1 . All four variables were significantly different across the first three groups (P < 0.05) by ANOVA (Fig. 1, A) and KruskallWallis (Fig. 1, B Medsger's total severity score was not significantly different between 7.79.8 and 9.812 range groups (P > 0.05). Age remained significant between all three groups. Table 1 shows correlation of ELF and its analytes with clinical characteristics. ELF score, TIMP-1 and PIIINP levels were higher in males than in females (P = 0.0197, P = 0.0107, P = 0.0108 respectively), in dcSSc than in lcSSc patients (P = 0.001, P = 0.0008, P < 0.0001 respectively) and showed no correlation with disease duration (P > 0.05). Furthermore, no statistically significant difference was found between patients with and without digital ulcers and among different videocapillaroscopy patterns (P > 0.05).
Regarding the therapy at the time of sampling, ELF score, TIMP-1 and HA levels were not significantly different (P > 0.05) between patients that were or were not on immunosuppressive/antirheumatic treatment. By contrast, PIIINP level was significantly higher in the group of patients on immunosuppressive/antirheumatic therapy [median (range) = 7.19 (1.1-34.63) vs 5.83 (0.91-21.27), P = 0.0098].
TIMP-1, PIIINP, HA and ELF score as markers of skin and lung fibrosis
Confirming results of the previous study, ELF score significantly correlated with the degree of skin involvement as assessed by mRSS (r = 0.37, P < 0.0001) and skin severity according to Medsger's severity scale (r = 0.31, P < 0.0001), with PIIINP, among its components, showing the most significant correlation (r = 0.30, P < 0.0001 for both) ( Table 1) . TIMP-1 and ELF score were significantly higher in patients with flexion contractures (P = 0.0012 and P = 0.04). With respect to lung involvement, all markers were significantly higher in patients with dyspnoea (TIMP-1 and ELF score P < 0.0001; PIIINP = 0.0004; HA P = 0.0005) and correlated with New York Heart Association class severity (P < 0.0001 for all). TIMP-1 and PIIINP levels were higher in patients with lung fibrosis assessed by chest HRCT scan (P = 0.0047 and P = 0.0308 respectively). All markers inversely correlated with DLCO% (P < 0.0001 for all, except for HA P = 0.0115). TIMP-1 and PIIINP inversely correlated with FVC% (r = À0.21, P = 0.0012; r = À0.26, P = 0.0001 respectively) and TLC% (r = À0.32, P < 0.0001; r = À0.28, P < 0.0001 respectively). ELF score inversely correlated with TLC% (r = À0.20, P = 0.0036). HA and, subsequently, ELF score, were significantly higher in patients with pulmonary arterial hypertension (PAH) (P = 0.0001 and P = 0.0005 respectively). Significant correlation was found between ELF score, TIMP-1, PIIINP, HA and total disease severity [10] and activity [9] (P < 0.0001 for the first three markers, P = 0.0001 for the fourth one) confirming results of the original study [6] .
Independent associations of ELF score, PIIINP, TIMP and HA Clinical variables found statistically significant in univariate analysis were included in multiple regression analysis. When ELF score was set as the dependent variable, a model including age (standardized coefficient beta = 0.482, P < 0.001), mRSS (standardized coefficient beta = 0.279, P < 0.001), and DLCO % (standardized coefficient beta = À0.199, P = 0.005) as predictors was obtained. Stepwise regression modelling with each one of the remaining markers of ELF test as the outcome variable showed that TIMP-1 was independently associated with gender (standardized coefficient beta = 0.291, P = 0.001), FVC% (standardized coefficient beta = À0.273, P = 0.002), age (standardized coefficient beta = 0.243, P = 0.003), ESR (standardized coefficient beta = 0.204, P = 0.012); PIIINP was independently associated with mRSS (standardized coefficient beta = 0.409, P < 0.001) and DLCO% (standardized coefficient beta = À0.23, P = 0.008); HA was independently associated with age (standardized coefficient beta = 0.445, P < 0.001) and mRSS (standardized coefficient beta = 0.244, P < 0.001).
Discussion
This is the first study assessing the value of the ELF score in a multicentre SSc patients cohort. The data presented in this study confirm in a second independent multicentre cohort the results of our original study [6] and indicate that the ELF score and its components are markers of fibrosis in SSc patients and are independently associated with skin and lung involvement. Indeed, ELF score and the single markers were significantly higher in patients with dcSSc, severe skin involvement, fibrosis on chest HRCT scan, abnormal pulmonary function and DLCO. The higher PIIINP level of patients on immunosuppressive therapy is consistent with published data and may reflect a higher level of ECM turnover [11] . By contrast, ELF and the single markers showed no difference in patients with digital ulcers or with specific videocapillaroscopy patterns compared with patients without signs of severe vasculopathy. The significant correlation of HA and, subsequently, of ELF score, with PAH, not found in the first study, might reflect the role of HA in pulmonary vascular remodeling [12, 13] .
As in the first study, here we analysed, and subsequently validated, the ELF test in a cohort of SSc patients. Merging the two cohort studies' results, these data are now confirmed in 457 patients enrolled in seven different SSc centres. The significant correlation with age in both studies is driven by HA and warrants a large healthy controls cohort assessment of ELF score in order to develop a new algorithm corrected by age. Furthermore, the score was originally developed on chronic liver fibrosis diseases and a new score, SSc-specific, is needed based on the weight and statistical significance of the single biomarkers in this condition. Indeed, the ELF score brackets have been determined as a best fit with the semiquantitative scoring of fibrosis in liver biopsies [5] . The lack of significant difference in mRSS between the first two brackets reflects the need for a design of a SSc specific score. A limitation of this study is the cross-sectional nature that was unable to assess the sensitivity to change of these biomarkers and their predictive value for progression of skin and lung fibrosis. Studies addressing these aspects are currently ongoing.
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